We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim has secured the option to license a cystic fibrosis gene therapy. The agreement will see Boehringer work with British academics and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based gene therapy treatment for cysti